- Home
- MTR vs GLMD Comparison
MTR vs GLMD Comparison
Compare MTR & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTR | GLMD |
|---|---|---|
| Founded | 1979 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 6.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MTR | GLMD |
|---|---|---|
| Price | $4.30 | $0.78 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.2K | ★ 82.8K |
| Earning Date | 04-02-2026 | 11-26-2025 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $623,288.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.03 | $0.73 |
| 52 Week High | $10.42 | $3.50 |
Technical Indicators
Market Signals| Indicator | MTR | GLMD |
|---|---|---|
| Relative Strength Index (RSI) | 48.40 | 35.40 |
| Support Level | $4.20 | $0.81 |
| Resistance Level | $4.87 | $0.88 |
| Average True Range (ATR) | 0.21 | 0.06 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 33.92 | 26.53 |
Price Performance
Historical ComparisonAbout MTR Mesa Royalty Trust
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.